Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed a long-term license agreement with Fujirebio Inc. to make its biomarker assay Procalcitonin (PCT) available on the Lumipulse™ family of laboratory instruments, using the chemiluminescent enzyme immunoassay (CLEIA) technology. The agreement focuses on Japan, where Fujirebio's Lumipulse product line is placed in a significant number of hospitals and clinical reference labs and will be extended with future placements of Lumipulse platforms in other markets worldwide.

The PCT assay is available worldwide on several different laboratory instruments from strategic license partners. In Europe, the PCT test, which has been the gold standard for the early detection of sepsis in critically ill patients, helps doctors to make an early determination whether an infection is bacterial or viral and quickly provides information on the severity of a patient's condition for appropriate treatment and therapy monitoring. In Japan, the PCT assay is used in patients suspected of having sepsis. Broader availability of PCT testing for diagnosing sepsis will lead to improved hospital management.

"This agreement with Fujirebio ensures that PCT testing will be available to a much broader patient base, helping to improve patient's outcome," said Marc Tremblay, president of Thermo Fisher Scientific's Clinical Diagnostics business. "Through the earlier detection of sepsis, healthcare providers can offer much better treatment to their patients and also achieve dramatic cost-savings."

Source: Thermo Fisher Scientific

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2019, April 30). Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing. News-Medical. Retrieved on August 04, 2021 from https://www.news-medical.net/news/20121121/Fujirebio-Thermo-Fisher-sign-license-agreement-for-broad-availability-of-PCT-testing.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing". News-Medical. 04 August 2021. <https://www.news-medical.net/news/20121121/Fujirebio-Thermo-Fisher-sign-license-agreement-for-broad-availability-of-PCT-testing.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing". News-Medical. https://www.news-medical.net/news/20121121/Fujirebio-Thermo-Fisher-sign-license-agreement-for-broad-availability-of-PCT-testing.aspx. (accessed August 04, 2021).

  • Harvard

    Thermo Fisher Scientific Inc.. 2019. Fujirebio, Thermo Fisher sign license agreement for broad availability of PCT testing. News-Medical, viewed 04 August 2021, https://www.news-medical.net/news/20121121/Fujirebio-Thermo-Fisher-sign-license-agreement-for-broad-availability-of-PCT-testing.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Thermo Fisher Scientific launches two breakthrough imaging filters that take cryo-EM to a new level